Logo
x

Search

Subscribe Now

Sanofi

Sanofi and Regeneron Reports the EC’s Approval of Dupixent (Dupilumab) for Young Children with Eosinophilic Esophagitis (EoE)

Sanofi and Regeneron Reports the EC’s Approval of Dupixent (Dupilumab) for Young Children with Eosinophilic Esophagitis (EoE)

  • November 6, 2024
Sanofi Collaborates with Orano Med for the Development of Next-Generation Radioligand Therapies

Sanofi Collaborates with Orano Med for the Development of Next-Generation Radioligand Therapies

  • October 17, 2024
Sanofi and Regeneron’s Dupixent Receives the US FDA’s and NMPA’s Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

Sanofi and Regeneron’s Dupixent Receives the US FDA’s and NMPA’s Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

  • September 30, 2024
Sanofi and Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Eosinophilic Esophagitis (EoE) in Children

Sanofi and Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Eosinophilic Esophagitis (EoE) in Children

  • September 23, 2024
Sanofi Reports the P-III (HERCULES) Study Results of Tolebrutinib for Treating Non-Relapsing Secondary Progressive Multiple Sclerosis (nrSPMS)

Sanofi Reports the P-III (HERCULES) Study Results of Tolebrutinib for Treating Non-Relapsing Secondary Progressive Multiple Sclero...

  • September 20, 2024
Sanofi and Regeneron’s Dupixent Receives the US FDA’s Approval to Treat Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sanofi and Regeneron’s Dupixent Receives the US FDA’s Approval to Treat Adolescents with Chronic Rhinosinusitis with Nasal Polyps...

  • September 16, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.